Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
18.94 USD   -0.53%
09/27Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société DECIPHERA PHARMACEUTICALS, INC.
09/12Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
09/11Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT..
BU
09/10Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation D..
BU
09/01Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Le..
BU
08/19Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5..
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Stud..
BU
08/04Deciphera Pharmaceuticals : Announces Second Quarter 2022 Financial Results - Form 8-K
PU
08/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
08/04Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
BU
07/28Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and H..
BU
07/15Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5..
BU
06/24Deciphera Pharmaceuticals, Inc. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/16Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
BU
06/02Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
BU
05/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
05/04Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
BU
05/02Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
AQ
05/02Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Con..
BU
04/29Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
BU
04/28Deciphera Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Financial St..
AQ
04/27Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-..
BU
04/26Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Fu..
BU
04/26Deciphera Pharmaceuticals, Inc. : Results of Operations and Financial Condition, Other Eve..
AQ
04/12Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR A..
BU
04/11Sprint Bioscience presents preclinical VPS34 data at AACR 2022 Annual Meeting
AQ
03/09Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
BU
02/11Deciphera Pharmaceuticals : EDITED TRANSCRIPT - Form 8-K
PU
02/08Deciphera Pharmaceuticals : Announces Fourth Quarter and Full Year 2021 Financial Results ..
PU
02/08Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial R..
BU
02/02Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
BU
02/01Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Resul..
BU
01/24Deciphera Pharmaceuticals : Presents Results from the INTRIGUE Phase 3 Clinical Study at t..
PU
01/24Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
01/24Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at ..
BU
01/10Deciphera Pharmaceuticals : Provides Corporate Update and Highlights Key 2022 Corporate Mi..
PU
01/10Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
01/10Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate M..
BU
01/03Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Co..
BU
2021Deciphera Announces Approval of QINLOCK in the United Kingdom for the Treatment of Four..
AQ
2021Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fou..
BU
2021Deciphera Pharmaceuticals : Announces Restructuring to Prioritize Clinical Development Pro..
PU
2021Deciphera Pharmaceuticals, Inc. : Costs Associated with Exit or Disposal Activities, Other..
AQ
2021Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Pr..
BU
2021Deciphera Pharmaceuticals : Receives European Commission Approval of QINLOCK® for the Trea..
PU
2021Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Other Events, Financial Statem..
AQ
2021Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth..
BU
2021Deciphera Pharmaceuticals, Inc. : Other Events (form 8-K)
AQ
2021Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical..
AQ
2021Deciphera Pharmaceuticals Announces Top-line Results from the INTRIGUE Phase 3 Clinical..
PU
2021Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Other Events, Financial Statem..
AQ
2021Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical..
BU
2021Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results - Form 8..
PU
2021DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
2021Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
BU
2021Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Con..
BU
2021Deciphera Pharmaceuticals : Announces Approval of QINLOCK® in Switzerland for the Treatmen..
BU
2021Deciphera Pharmaceuticals : Presents Preclinical Data from DCC-3116 Program at the AACR-NC..
BU
2021Deciphera Pharmaceuticals : Submission of Matters to a Vote of Security Holders (form 8-K/..
AQ
2021Deciphera Pharmaceuticals : Announces Positive CHMP Opinion for QINLOCK® for the Treatment..
PU
2021Deciphera Pharmaceuticals : Announces Positive CHMP Opinion for QINLOCK® for the Treatment..
BU
2021Deciphera Pharmaceuticals : Presents New Clinical Study Results Across Pipeline at the Eur..
PU
2021Deciphera Pharmaceuticals, Inc. : Regulation FD Disclosure, Other Events, Financial Statem..
AQ
2021Deciphera Pharmaceuticals : Presents New Clinical Study Results Across Pipeline at the Eur..
BU
2021Deciphera Pharmaceuticals : to Host Virtual Investor Event Featuring Key Opinion Leaders t..
BU
2021Deciphera Pharmaceuticals, Inc. : to Present at the 19th Annual Morgan Stanley Global Heal..
BU
2021Deciphera Pharmaceuticals : Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Pat..
PU
2021Sprint Bioscience : licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals
AQ
2021Deciphera Pharmaceuticals : Management's Discussion and Analysis of Financial Condition an..
AQ
2021Deciphera Pharmaceuticals, Inc. : Announces Second Quarter 2021 Financial Results
BU
2021Deciphera Pharmaceuticals : to Announce Second Quarter 2021 Financial Results and Host Con..
BU
2021Deciphera Pharmaceuticals : Announces First Patient Treated in Phase 1 Study of DCC-3116 i..
BU
2021Deciphera Pharmaceuticals, Inc. : Submission of Matters to a Vote of Security Holders (for..
AQ
2021Deciphera Pharmaceuticals : Presents Data from QINLOCK® and Rebastinib Programs at the 202..
BU
2021Deciphera Pharmaceuticals, Inc. : to Present at Upcoming Investor Conferences
BU
2021Deciphera Pharmaceuticals, Inc. : Announces First Quarter 2021 Financial Results
BU
1  2  3Next
Upcoming event on DECIPHERA PHARMACEUTICALS, INC.